Phase 4Status unknown

Efficacy of Generic vs. Original Rosuvastatin 20 mg and Ezetimibe 10 mg Free-Combination Therapy on LDL-C Reduction: A Non-inferiority Trial

Sponsor
Berlin Pharmaceutical Industry Co.,Ltd (Industry)
Enrollment
108 planned
Conditions
Hypercholesterolemia in High or Very High Cardiovascular Risk Patients Rosuvastatin, Ezetimibe, Hypercholesterolemia, Dyslipidemia, Cardiovascular Diseases, LDL Cholesterol; Rosuvastatin, Ezetimibe, Hypercholesterolemia, Dyslipidemia, Cardiovascular Diseases, LDL Cholesterol
Interventions
Participants will receive the original formulation of Rosuvastatin (Crestor) 20 mg combined with Ezetimibe (Ezetrol) 10 mg orally once daily after dinner for 12 weeks; Active Comparator Drug,Experimental Drug; Original Combination Group,Generic Combination Group
Ages
adults, older adults
Registry
TCTR20260920003

Full record on the Thai Clinical Trials RegistrySource: WHO ICTRP, processed November 9, 2026

Primary outcomes

  • Change in Low-Density Lipoprotein Cholesterol (LDL-C) level 12 weeks Percentage change in blood LDL-C concentration (mg/dL) from baseline.

History

  1. Study completion expected

  2. Last registry update

  3. Started

  4. Registered

In the news